Work

FIGURE 2 from Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma

Year: 2023

Type: other

Abstract: Survival characteristics. PFS (A) and OS (B) for the overall cohort, in months. CI, confidence interval; NR, not reached.

DOI: 10.1158/2767-9764.23713979.v1

Authors: Stephanie L. Alden, Mir Lim, Chester Kao, Daniel Shu, Amit G. Singal, Anne Noonan, Paige Griffith, Marina Baretti, Won Jin Ho, Ihab Kamel, Mark Yarchoan, David Hsiehchen

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4384821527

Cites:

Cited by:

Related to: 10